Recent drug approvals have increased the availability of biologic therapies for inflammatory bowel disease (IBD), making it difficult for patients with ulcerative colitis (UC) and Crohn’s disease (CD) to navigate treatment options.
Dr Brennan Spiegel and colleagues from California, USA developed a conjoint analysis to examine patient decision-making surrounding biologic medicines for IBD.
The research team used the results to create an online patient decision aid that generates a unique “preferences report” for each patient to assist with shared decision-making with their provider.
The team administered an adaptive choice-based conjoint survey to IBD patients that quantifies the relative importance of biologic attributes in decision making.
The conjoint software determined individual patient preferences by calculating part-worth utilities for each attribute.
|Those with UC were more likely to value therapeutic efficacy|
|American Journal of Gastroenterology|
The researchers conducted regression analyses to determine if demographic and disease characteristics predicted how patients made decisions.
The team found 640 patients that completed the survey.
The research team noted that demographics and IBD characteristics did not predict individual patient preferences, and the main exception was IBD type.
When compared to UC, CD patients were more likely to report side effect profile as most important.
Conversely, those with UC were more likely to value therapeutic efficacy.
Dr Spiegel's team concludes, "Biologic decision-making is highly personalized; demographic and disease characteristics poorly predict individual preferences, indicating that IBD patients are unique and difficult to statistically categorize."
"The online decision tool resulting from this study may be used by patients to support shared decision-making and optimize personalized biologic selection with their provider."